The AI biotech and capex arms race is reshaping tech war—who’s winning, and who’s overbuilding?

US policymakers are increasingly framing China’s biotechnology sector as the next front in the broader technology contest, signaling that medical innovation will be treated through a strategic and security lens rather than purely as commercial progress. The framing appears alongside a wider “tech war” narrative in which advanced capabilities—whether AI, biotech, or enabling infrastructure—are evaluated for national power implications. At the same time, European AI researchers warn that Europe cannot credibly “wait and see” without eroding its economic competitiveness against the US and China. Their argument is explicit: delaying participation in the AI arms race risks surrendering the industrial base needed to compete in downstream markets. Strategically, the cluster points to a convergence of two battlegrounds: AI-driven compute and data infrastructure, and biotech innovation that can translate into future therapeutics, diagnostics, and potentially dual-use capabilities. The US-China dynamic benefits actors who can secure supply chains, talent, and regulatory access while restricting adversary progress through export controls, procurement screening, and investment scrutiny. Europe’s dilemma is that it faces a coordination and funding gap, yet it is being pulled into the same competitive logic by the need to maintain industrial relevance. In this environment, “good news” in medical innovation is not automatically treated as benign; it is being reinterpreted as strategic capacity that could strengthen a rival’s long-term leverage. Market implications are immediate for AI infrastructure and the balance sheets behind it. The capex “depreciation time bomb” thesis suggests that Big Tech’s heavy spending on AI infrastructure—highlighted across Google, Meta, Amazon, and Microsoft—may create accelerated depreciation pressure and cash-flow stress if demand ramps slower than expected or if hardware utilization lags. Tesla’s AI progress is also being treated as a proxy signal for how effectively AI investment converts into operational outcomes, with analysts at Oppenheimer reportedly suggesting that monitoring Tesla’s cash spending could clarify whether the strategy is compounding or burning capital. For investors, the direction is toward higher scrutiny of capex efficiency metrics, cloud and semiconductor demand durability, and the credit risk embedded in large-scale AI buildouts. Next, watch for policy signals that formalize biotech as a security domain, such as expanded screening of medical R&D partnerships, tighter rules on advanced lab equipment, and procurement restrictions tied to national security. On the AI side, key indicators include utilization rates of AI data centers, cloud margin trajectories, and evidence that capex is translating into measurable product performance rather than only expanding capacity. For Europe, the trigger points are funding commitments, industrial policy coordination, and whether governments can close the gap without relying exclusively on US or Chinese supply chains. Escalation would look like broader biotech controls and more aggressive AI export or procurement constraints, while de-escalation would require clearer assurances on medical innovation governance and more transparent cross-border research pathways.

Geopolitical Implications

• 01

  Biotech is being pulled into security policy, increasing the likelihood of tighter cross-border research and investment controls.

• 02

  Europe’s pressure to participate could accelerate fragmentation of AI supply chains and intensify competition for capacity, chips, and talent.

• 03

  AI infrastructure buildouts may become strategic levers, with security screening shaping who scales faster and cheaper.

• 04

  If capex efficiency disappoints, financial stress could force strategic reprioritization by both firms and governments.

Key Signals

• —Expanded biotech security screening and partnership vetting in the US.
• —Utilization and margin trends for AI data centers and cloud workloads.
• —Capex guidance changes and depreciation/cash-flow commentary from Big Tech.
• —Tesla cash spending patterns and measurable AI performance milestones.